Scholar Rock Holding (SRRK) closed at $48.00 on November 10, 2026, down 6.9% from the previous close, on volume of 1,830,269 shares (30-day average 1,624,449).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 9, 2026 | Seagull Ratio With Put Spread | 20-Nov-2640 P : 45[3x] P : 55[4x] C | 2,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Analysts Offer Insights on NA Companies: SpaceX (SPCX) and Scholar Rock Holding (SRRK)
TipRanks (Tue, 10-Nov 4:20 PM ET)
BioNTech to buy Scholar Rock Priority Review Voucher for $205M
Seeking Alpha News (Tue, 10-Nov 8:08 AM ET)
Scholar Rock Agrees to Sell Priority Review Voucher
TipRanks (Tue, 10-Nov 7:33 AM ET)
Scholar Rock GAAP EPS of -$0.81 beats by $0.05, revenue of $0.57M beats by $0.29M
Seeking Alpha News (Tue, 10-Nov 7:11 AM ET)
Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Business Wire (Tue, 10-Nov 7:00 AM ET)
Here are the major earnings before the open Tuesday
Seeking Alpha News (Mon, 9-Nov 6:00 PM ET)
Scholar Rock Q3 2026 Earnings Preview
Seeking Alpha News (Mon, 9-Nov 9:39 AM ET)
Scholar Rock to Present at Upcoming Investor Conferences
Business Wire (Tue, 3-Nov 8:00 AM ET)
Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026
Business Wire (Tue, 20-Oct 8:00 AM ET)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 16-Oct 4:15 PM ET)
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Scholar Rock Holding trades on the NASDAQ stock market under the symbol SRRK.
As of November 10, 2026, SRRK stock price declined to $48.00 with 1,830,269 million shares trading.
SRRK has a beta of 0.90, meaning it tends to be less sensitive to market movements. SRRK has a correlation of 0.04 to the broad based SPY ETF.
SRRK has a market cap of $5.85 billion. This is considered a Mid Cap stock.
Last quarter Scholar Rock Holding reported $0 in Revenue and -$.84 earnings per share. This fell short of revenue expectation by $-2 million and met earnings estimates .
In the last 3 years, SRRK traded as high as $61.76 and as low as $6.76.
The top ETF exchange traded funds that SRRK belongs to (by Net Assets): VTI, IWM, XBI, VB, VXF.
SRRK has outperformed the market in the last year with a price return of +65.8% while the SPY ETF gained +12.9%. However, in the short term, SRRK had mixed performance relative to the market. It has underperformed in the last 3 months, returning -9.3% vs -2.8% return in SPY. But in the last 2 weeks, SRRK shares have fared better than the market returning +15.1% compared to SPY -2.0%.
SRRK support price is $50.04 and resistance is $53.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRRK shares will trade within this expected range on the day.
